Cardiotoxicity of ErbB2-targeted therapies and its impact on drug development, a spotlight on trastuzumab

Breast Cancer Therapy–Related Cardiac Dysfunction in Adult Women Treated in Routine Clinical Practice: A Population-Based Cohort Study

(2016) Paaladinesh Thavendiranathan et al.   JOURNAL OF CLINICAL ONCOLOGY

Trastuzumab, but Not Pertuzumab, Dysregulates HER2 Signaling to Mediate Inhibition of Autophagy and Increase in Reactive Oxygen Species Production in Human Cardiomyocytes

(2016) Nishant Mohan et al.   MOLECULAR CANCER THERAPEUTICS

Cardiovascular Toxic Effects of Targeted Cancer Therapies

(2016) Javid J. Moslehi   NEW ENGLAND JOURNAL OF MEDICINE

Randomized Phase II Study of Duligotuzumab (MEHD7945A) vs. Cetuximab in Squamous Cell Carcinoma of the Head and Neck (MEHGAN Study)

(2016) Jérôme Fayette et al.   Frontiers in Oncology

Pro1170 Ala polymorphism in HER2-neu is associated with risk of trastuzumab cardiotoxicity

(2015) Sasha E Stanton et al.   BMC CANCER

A proof of concept trial of the anti-EGFR antibody mixture Sym004 in patients with squamous cell carcinoma of the head and neck

(2015) J.-P. Machiels et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Use of biomarkers for the assessment of chemotherapy-induced cardiac toxicity

(2015) Eric S. Christenson et al.   CLINICAL BIOCHEMISTRY

Role and mechanisms of resistance of epidermal growth factor receptor antagonists in the treatment of colorectal cancer

(2015) Karim Rihawi et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Pertuzumab-induced cardiotoxicity: safety compared with trastuzumab

(2015) Mehmet AN Sendur et al.   Future Oncology

Enhanced QSAR models for drug-triggered inhibition of the main cardiac ion currents

(2015) Barbara Wiśniowska et al.   JOURNAL OF APPLIED TOXICOLOGY

ERBB2 triggers mammalian heart regeneration by promoting cardiomyocyte dedifferentiation and proliferation

(2015) Gabriele D’Uva et al.   NATURE CELL BIOLOGY

Erratum: Cardiotoxicity of anticancer treatments

(2015) Michael S. Ewer et al.   Nature Reviews Cardiology

Chemotherapy-Induced Cardiotoxicity: Detection, Prevention, and Management

(2014) Judy Truong et al.   CANADIAN JOURNAL OF CARDIOLOGY

Trastuzumab-induced recruitment of Csk-homologous kinase (CHK) to ErbB2 receptor is associated with ErbB2-Y1248 phosphorylation and ErbB2 degradation to mediate cell growth inhibition

(2014) Milos Dokmanovic et al.   CANCER BIOLOGY & THERAPY

ERBB Receptors: From Oncogene Discovery to Basic Science to Mechanism-Based Cancer Therapeutics

(2014) Carlos L. Arteaga et al.   CANCER CELL

Signalling between microvascular endothelium and cardiomyocytes through neuregulin

(2014) Emily M. Parodi et al.   CARDIOVASCULAR RESEARCH

Trastuzumab-Induced Cardiotoxicity: Is it a Personalized Risk?

(2014) Gerard Milano et al.   CURRENT DRUG TARGETS

Anti-HER2 Cancer Therapy and Cardiotoxicity

(2014) Tania Babar et al.   CURRENT PHARMACEUTICAL DESIGN

Randomized phase II trial of nimotuzumab plus irinotecan versus irinotecan alone as second-line therapy for patients with advanced gastric cancer

(2014) Taroh Satoh et al.   Gastric Cancer

Safety and Efficacy of Neratinib in Combination With Capecitabine in Patients With Metastatic Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer

(2014) Cristina Saura et al.   JOURNAL OF CLINICAL ONCOLOGY

Doxorubicin and Trastuzumab Regimen Induces Biventricular Failure in Mice

(2014) Giuseppina Milano et al.   JOURNAL OF THE AMERICAN SOCIETY OF ECHOCARDIOGRAPHY

Dacomitinib as first-line treatment in patients with clinically or molecularly selected advanced non-small-cell lung cancer: a multicentre, open-label, phase 2 trial

(2014) Pasi A Jänne et al.   LANCET ONCOLOGY

Antibodies to watch in 2015

(2014) Janice M Reichert   mAbs

Combination of Anti-HER3 Antibody MM-121/SAR256212 and Cetuximab Inhibits Tumor Growth in Preclinical Models of Head and Neck Squamous Cell Carcinoma

(2014) N. Jiang et al.   MOLECULAR CANCER THERAPEUTICS

Anthracycline-induced cardiotoxicity: Overview of studies examining the roles of oxidative stress and free cellular iron

(2014) Tomáš Šimůnek et al.   Pharmacological Reports

Effects of a second-generation human anti-ErbB2 ImmunoRNase on trastuzumab-resistant tumors and cardiac cells

(2014) C. D'Avino et al.   PROTEIN ENGINEERING DESIGN & SELECTION

Cardiovascular Toxicities from Systemic Breast Cancer Therapy

(2014) Shuang Guo et al.   Frontiers in Oncology

Serum Biomarkers for the Detection of Cardiac Toxicity after Chemotherapy and Radiation Therapy in Breast Cancer Patients

(2014) Sibo Tian et al.   Frontiers in Oncology

Rechanneling the cardiac proarrhythmia safety paradigm: A meeting report from the Cardiac Safety Research Consortium

(2013) Philip T. Sager et al.   AMERICAN HEART JOURNAL

HER2 Dimerization Inhibitor Pertuzumab - Mode of Action and Clinical Data in Breast Cancer

(2013) Nadia Harbeck et al.   Breast Care

Current challenges and clinical investigations of epidermal growth factor receptor (EGFR)- and ErbB family-targeted agents in the treatment of head and neck squamous cell carcinoma (HNSCC)

(2013) Roger B. Cohen   CANCER TREATMENT REVIEWS

Human Ether-a-Go-Go-Related Gene Channel Blockers and its Structural Analysis for Drug Design

(2013) N. S. Hari Narayana Moorthy et al.   CURRENT DRUG TARGETS

Cardiotoxicity of novel HER2-targeted therapies

(2013) Mehmet A.N. Sendur et al.   CURRENT MEDICAL RESEARCH AND OPINION

Recent Advances in Drug Design of Epidermal Growth Factor Receptor Inhibitors

(2013) P. Warnault et al.   CURRENT MEDICINAL CHEMISTRY

Phase I–IIa study of BMS-690514, an EGFR, HER-2 and -4 and VEGFR-1 to -3 oral tyrosine kinase inhibitor, in patients with advanced or metastatic solid tumours

(2013) Jean-Charles Soria et al.   EUROPEAN JOURNAL OF CANCER

A phase two randomised trial of neratinib monotherapy versus lapatinib plus capecitabine combination therapy in patients with HER2+ advanced breast cancer

(2013) Miguel Martin et al.   EUROPEAN JOURNAL OF CANCER

Cardiac toxicity in breast cancer patients treated with dual HER2 blockade

(2013) Antonis Valachis et al.   INTERNATIONAL JOURNAL OF CANCER

Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study

(2013) Sandra M Swain et al.   LANCET ONCOLOGY

Icotinib versus gefitinib in previously treated advanced non-small-cell lung cancer (ICOGEN): a randomised, double-blind phase 3 non-inferiority trial

(2013) Yuankai Shi et al.   LANCET ONCOLOGY

Speedy validation sought for new cardiotoxicity testing strategy

(2013) Kelly Rae Chi   NATURE REVIEWS DRUG DISCOVERY

Revolution dawning in cardiotoxicity testing

(2013) Kelly Rae Chi   NATURE REVIEWS DRUG DISCOVERY

Pharmacogenomics as a risk mitigation strategy for chemotherapeutic cardiotoxicity

(2013) Brian C Jensen et al.   PHARMACOGENOMICS

Drug attrition during pre-clinical and clinical development: Understanding and managing drug-induced cardiotoxicity

(2013) Nicola Ferri et al.   PHARMACOLOGY & THERAPEUTICS

Trastuzumab Alters the Expression of Genes Essential for Cardiac Function and Induces Ultrastructural Changes of Cardiomyocytes in Mice

(2013) M. Khair ElZarrad et al.   PLoS One

Cardiovascular Toxicities of Biological Therapies

(2013) Marianne Ryberg   SEMINARS IN ONCOLOGY

Bioactivation to an aldehyde metabolite—Possible role in the onset of toxicity induced by the anti-HIV drug abacavir

(2013) Nádia M. Grilo et al.   TOXICOLOGY LETTERS

Mechanisms of cardiotoxicity associated with ErbB2 inhibitors

(2012) Carmine Fedele et al.   BREAST CANCER RESEARCH AND TREATMENT

Phase I study of AEE788, a novel multitarget inhibitor of ErbB- and VEGF-receptor-family tyrosine kinases, in recurrent glioblastoma patients

(2012) David A. Reardon et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

The Dual-Targeted HER1/HER2 Tyrosine Kinase Inhibitor Lapatinib Strongly Potentiates the Cardiac Myocyte-Damaging Effects of Doxorubicin

(2012) Brian B. Hasinoff et al.   Cardiovascular Toxicology

The future of antibodies as cancer drugs

(2012) Janice M. Reichert et al.   DRUG DISCOVERY TODAY

Targeting the EGFR signaling pathway in cancer therapy

(2012) Parthasarathy Seshacharyulu et al.   EXPERT OPINION ON THERAPEUTIC TARGETS

Predictive model for L-type channel inhibition: multichannel block in QT prolongation risk assessment

(2012) Barbara Wiśniowska et al.   JOURNAL OF APPLIED TOXICOLOGY

Tyrosine kinase inhibitor (TKI)-induced cardiotoxicity: approaches to narrow the gaps between preclinical safety evaluation and clinical outcome

(2012) Baichun Yang et al.   JOURNAL OF APPLIED TOXICOLOGY

Risk of Heart Failure in Breast Cancer Patients After Anthracycline and Trastuzumab Treatment: A Retrospective Cohort Study

(2012) E. J. A. Bowles et al.   JNCI-Journal of the National Cancer Institute

Phase II Study of the Multitargeted Tyrosine Kinase Inhibitor XL647 in Patients with Non–Small-Cell Lung Cancer

(2012) M. Catherine Pietanza et al.   Journal of Thoracic Oncology

A phase I trial of gefitinib and nimotuzumab in patients with advanced non-small cell lung cancer (NSCLC)

(2012) Se Hyun Kim et al.   LUNG CANCER

On-target and Off-target-based Toxicologic Effects

(2012) Daniel G. Rudmann   TOXICOLOGIC PATHOLOGY

Characterization of Human-Induced Pluripotent Stem Cell–Derived Cardiomyocytes: Bioenergetics and Utilization in Safety Screening

(2012) Payal Rana et al.   TOXICOLOGICAL SCIENCES

Induced pluripotent stem cell derived cardiomyocytes as models for cardiac arrhythmias

(2012) Maaike Hoekstra et al.   Frontiers in Physiology

Pooled analysis of cardiac safety in patients with cancer treated with pertuzumab

(2011) D. Lenihan et al.   ANNALS OF ONCOLOGY

Herceptin, a recombinant humanized anti-ERBB2 monoclonal antibody, induces cardiomyocyte death

(2011) Krishna K. Singh et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Novel Toll-like receptor-4 deficiency attenuates trastuzumab (Herceptin) induced cardiac injury in mice

(2011) Nasser Ghaly Yousif et al.   BMC Cardiovascular Disorders

Comparison of preclinical cardiotoxic effects of different ErbB2 inhibitors

(2011) Carmine Fedele et al.   BREAST CANCER RESEARCH AND TREATMENT

How can we improve our understanding of cardiovascular safety liabilities to develop safer medicines?

(2011) HG Laverty et al.   BRITISH JOURNAL OF PHARMACOLOGY

Simulation of multiple ion channel block provides improved early prediction of compounds’ clinical torsadogenic risk

(2011) Gary R. Mirams et al.   CARDIOVASCULAR RESEARCH

Cardiovascular toxicity of anticancer-targeted therapy: emerging issues in the era of cardio-oncology

(2011) Emanuel Raschi et al.   Internal and Emergency Medicine

Phase I study of temsirolimus in combination with EKB-569 in patients with advanced solid tumors

(2011) Alan H. Bryce et al.   INVESTIGATIONAL NEW DRUGS

The Utility of Cardiac Biomarkers, Tissue Velocity and Strain Imaging, and Cardiac Magnetic Resonance Imaging in Predicting Early Left Ventricular Dysfunction in Patients With Human Epidermal Growth Factor Receptor II–Positive Breast Cancer Treated With Adjuvant Trastuzumab Therapy

(2011) Nazanin Fallah-Rad et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Zalutumumab plus best supportive care versus best supportive care alone in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck after failure of platinum-based chemotherapy: an open-label, randomised phase 3 trial

(2011) Jean-Pascal Machiels et al.   LANCET ONCOLOGY

Cardiotoxicity of kinase inhibitors: the prediction and translation of preclinical models to clinical outcomes

(2011) Thomas Force et al.   NATURE REVIEWS DRUG DISCOVERY

Risk of cardiac dysfunction with trastuzumab in breast cancer patients: A meta-analysis

(2010) Tao Chen et al.   CANCER TREATMENT REVIEWS

The Vulnerability of the Heart As a Pluricellular Paracrine Organ

(2010) Gilles W. De Keulenaer et al.   CIRCULATION RESEARCH

Phase II study of nimotuzumab, a humanized monoclonal anti-epidermal growth factor receptor (EGFR) antibody, in patients with locally advanced or metastatic pancreatic cancer

(2010) Dirk Strumberg et al.   INVESTIGATIONAL NEW DRUGS

Expression, localization, and regulation of the neuregulin receptor ErbB3 in mouse heart

(2010) Genís Campreciós et al.   JOURNAL OF CELLULAR PHYSIOLOGY

Trastuzumab-Induced Cardiotoxicity: Clinical and Prognostic Implications of Troponin I Evaluation

(2010) Daniela Cardinale et al.   JOURNAL OF CLINICAL ONCOLOGY

Recurrent myocardial infarction associated with gefitinib therapy

(2010) Donald R. Lynch et al.   JOURNAL OF THROMBOSIS AND THROMBOLYSIS

A randomized, phase II, dose-finding study of the pan-ErbB receptor tyrosine-kinase inhibitor CI-1033 in patients with pretreated metastatic breast cancer

(2009) Olivier Rixe et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Neuregulin1/ErbB4 Signaling Induces Cardiomyocyte Proliferation and Repair of Heart Injury

(2009) Kevin Bersell et al.   CELL

Cardiotoxic effects, or lack thereof, of anti-ErbB2 immunoagents

(2009) Gennaro Riccio et al.   FASEB JOURNAL

Potential of ErbB4 antibodies for cancer therapy

(2009) Maija Hollmén et al.   Future Oncology

Cardiotoxicity of Anticancer Drugs: The Need for Cardio-Oncology and Cardio-Oncological Prevention

(2009) Adriana Albini et al.   JNCI-Journal of the National Cancer Institute

Anticancer drugs and cardiotoxicity: Insights and perspectives in the era of targeted therapy

(2009) Emanuel Raschi et al.   PHARMACOLOGY & THERAPEUTICS

Cardiac ErbB-1/ErbB-2 mutant expression in young adult mice leads to cardiac dysfunction

(2008) Viswanathan Rajagopalan et al.   AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY

The role of Neuregulin-1β/ErbB signaling in the heart

(2008) Laura Pentassuglia et al.   EXPERIMENTAL CELL RESEARCH

Trastuzumab cardiotoxicity: biological hypotheses and clinical open issues

(2008) Emilio Bria et al.   EXPERT OPINION ON BIOLOGICAL THERAPY

ErbB receptors, their ligands, and the consequences of their activation and inhibition in the myocardium

(2008) Stephen J. Fuller et al.   JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY